Literature DB >> 28054529

A retrospective analysis of patients with head and neck cancer treated with radiation, hyperthermia, and cetuximab: A brief report of outcome.

Nagraj G Huilgol1.   

Abstract

PURPOSE: Advanced head and neck cancer continues to have a dismal outcome. Chemoradiation remains the current standard of care. Chemoradiation has not achieved the desired increase in survival in locally advanced head and neck cancer. This is a retrospective analysis of six patients treated with hyperthermia, radiation therapy, and cetuximab. We wished to determine if this combination treatment would further improve the outcome.
MATERIALS AND METHODS: Six patients with squamous cell cancer of the head and neck region were treated with hyperthermia, cetuximab, and radiation therapy. The end points assessed were acute toxicity and immediate response.
RESULTS: All the six patients received the planned doses of cetuximab and radiation therapy. Two patients did not complete the planned hyperthermia sessions. All patients developed mucositis and acneiform rashes. None had thermal burns. One hundred percent complete response was observed in all the patients.
CONCLUSION: Addition of hyperthermia to cetuximab and radiation therapy is feasible and shows impressive response rates with manageable toxicity profile. Further studies evaluating the same are needed to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 28054529     DOI: 10.4103/0973-1482.194600

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  2 in total

1.  Retrograde superselective intra-arterial chemoradiotherapy combined with hyperthermia and cetuximab for carcinoma of the buccal mucosa with N3 lymph node metastasis: a case report.

Authors:  Kaname Sakuma; Toshiyuki Koizumi; Kenji Mitsudo; Jun Ueda; Yuichiro Hayashi; Toshinori Iwai; Makoto Hirota; Mitomu Kioi; Haruka Yoshii; Hisashi Kaizu; Masaharu Hata; Akira Tanaka; Iwai Tohnai
Journal:  Oral Radiol       Date:  2018-02-05       Impact factor: 1.852

2.  Oncology Gold Standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck.

Authors:  Govind Babu; Ankur Bahl; G S Bhattacharya; K T Bhowmik; P S Dattatraya; Nikhil Ghadyalpatil; S M Karandikar; Padmaj Kulkarni; Nithya Sridharan; Purvish Parikh; Kumar Prabhash; T Raja; S Rajasundaram; S Subramanian; Kaustav Talapatra; Ashok Vaid
Journal:  South Asian J Cancer       Date:  2017 Oct-Dec
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.